Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drug Safety
Erschienen in: Drug Safety 2/2018

01.02.2018 | Current Opinion

From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources

verfasst von: Gianluca Trifirò, Janet Sultana, Andrew Bate

Erschienen in: Drug Safety | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

In the last decade ‘big data’ has become a buzzword used in several industrial sectors, including but not limited to telephony, finance and healthcare. Despite its popularity, it is not always clear what big data refers to exactly. Big data has become a very popular topic in healthcare, where the term primarily refers to the vast and growing volumes of computerized medical information available in the form of electronic health records, administrative or health claims data, disease and drug monitoring registries and so on. This kind of data is generally collected routinely during administrative processes and clinical practice by different healthcare professionals: from doctors recording their patients’ medical history, drug prescriptions or medical claims to pharmacists registering dispensed prescriptions. For a long time, this data accumulated without its value being fully recognized and leveraged. Today big data has an important place in healthcare, including in pharmacovigilance. The expanding role of big data in pharmacovigilance includes signal detection, substantiation and validation of drug or vaccine safety signals, and increasingly new sources of information such as social media are also being considered. The aim of the present paper is to discuss the uses of big data for drug safety post-marketing assessment.
Literatur
1.
2.
3.
Index for excerpts from the American Recovery and Reinvestment Act of 2009. Health Information Technology (HITECH) Act 2009. 112–64.
4.
Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc. 2013;20:117–21.CrossRefPubMed
5.
Wagholikar KB, Sundararajan V, Deshpande AW. Modeling paradigms for medical diagnostic decision support: a survey and future directions. J Med Syst. 2012;36:3029–49.CrossRefPubMed
6.
Sullivan P, Goldmann D. The promise of comparative effectiveness research. JAMA. 2011;305:400–1.CrossRefPubMed
7.
Bate A, Juniper J, Lawton AM, Thwaites RM. Designing and incorporating a real world data approach to international drug development and use: what the UK offers. Drug Discov Today. 2016;21(3):400–5.CrossRefPubMed
8.
Trifirò G, Vaishali P, Schuemie MJ, Coloma P, Gini P, Herings R, Mazzaglia G, Picelli P, Nicotra F, Pedersen L, van der Lei J, Sturkenboom M, on behalf of the EU-ADR consortium. Can the EU-ADR database network detect timely drug safety signals? Pharmacoepidemiol Drug Saf. 2012;21(Supp. 3):173.
9.
Bate A, Pariente A, Hauben M, Bégaud B. Quantitative signal detection and analysis in pharmacovigilance. Mann’s Pharmacovigil. 2014:331–54.
10.
11.
12.
13.
Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network—improving the evidence of medical-product safety. N Engl J Med. 2009;361:645–7.CrossRefPubMed
14.
Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M, EU-ADR Consortium. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1–11.CrossRefPubMed
15.
16.
Trifiro G, Fourrier-Reglat A, Sturkenboom MC, DíazAcedo C, Van Der Lei J, EU-ADR Group. The EU-ADR project: preliminary results and perspective. Stud Health Technol Inform. 2009;148:43–9.PubMed
17.
Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour JC, Mazzaglia G, Giaquinto C, Fornari C, Herings R, Molokhia M, Pedersen L, Fourrier-Réglat A, Fieschi M, Sturkenboom M, van der Lei J, Pariente A, Trifirò G, EU-ADR consortium. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc. 2013;20(1):184–92.CrossRefPubMed
18.
Trifirò G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, Bonhoeffer J, Schuemie M, van der Lei J, Sturkenboom M. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551–61.CrossRefPubMed
19.
de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifirò G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC, EU-ADR consortium. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. Br J Clin Pharmacol. 2015;80(2):304–14.CrossRefPubMedPubMedCentral
20.
Trifirò G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Frøslev T, Molokhia M, Diemberger I, Sturkenboom MCJM. Use of azithromycin and risk of ventricular arrhythmia. CMAJ. 2017;189(15):E560–8.CrossRefPubMedPubMedCentral
21.
Blake KV, Devries CS, Arlett P, Kurz X, Fitt H. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21(7):690–6.CrossRefPubMed
22.
Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–21.CrossRefPubMedPubMedCentral
23.
Bisgin H, Liu Z, Fang H, Xu X, Tong W. Mining FDA drug labels using an unsupervised learning technique-topic modeling. BMC Bioinform. 2011;12(Suppl 10):S11.CrossRef
24.
Orre R, Bate A, Norén GN, Swahn E, Arnborg S, Edwards IR. A Bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. Int J Neural Syst. 2005;15(03):207–22.CrossRefPubMed
25.
Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase®. Drug Saf. 2017;40(1):81–90.CrossRefPubMed
26.
Alvager T, Smith TJ, Vijai F. Neural-network applications for analysis of adverse drug reactions. Biomed Instrum Technol. 1993;27(5):408–11.PubMed
27.
Reps JM, Garibaldi JM, Aickelin U, Gibson JE, Hubbard RB. A supervised adverse drug reaction signalling framework imitating Bradford Hill’s causality considerations. J Biomed Inform. 2015;56:356–68.CrossRefPubMed
28.
Walker AM, Zhou X, Ananthakrishnan AN, Weiss LS, Shen R, Sobel RE, Bate A, Reynolds RF. Computer-assisted expert case definition in electronic health records. Int J Med Inform. 2016;86:62–70.CrossRefPubMed
29.
Luo Y, Thompson WK, Herr TM, Zeng Z, Berendsen MA, Jonnalagadda SR, Carson MB, Starren J. Natural language processing for EHR-based pharmacovigilance: a structured review. Drug Saf. 2017. (epub ahead of print).
30.
Abacha AB, Chowdhury MF, Karanasiou A, Mrabet Y, Lavelli A, Zweigenbaum P. Text mining for pharmacovigilance: using machine learning for drug name recognition and drug–drug interaction extraction and classification. J Biomed Inform. 2015;58:122–32.CrossRefPubMed
31.
Shang N, Xu H, Rindflesch TC, Cohen T. Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform. 2014;52:293–310.CrossRefPubMedPubMedCentral
32.
Nikfarjam A, Sarker A, O’Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015;22(3):671–81.PubMedPubMedCentral
33.
Sarker A, Gonzalez G. Portable automatic text classification for adverse drug reaction detection via multi-corpus training. J Biomed Inform. 2015;53:196–207.CrossRefPubMed
34.
35.
Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts. Drug Saf. 2017;40(4):317–31.CrossRefPubMedPubMedCentral
36.
Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez GJ. Utilizing social media data for pharmacovigilance: a review. Biomed Inform. 2015;54:202–12.CrossRef
37.
Yom-Tov E, Gabrilovich E. Postmarket drug surveillance without trial costs: discovery of adverse drug reactions through large-scale analysis of web search queries. J Med Internet Res. 2013;15(6):e124.CrossRefPubMedPubMedCentral
38.
Ventola LC. Mobile devices and apps for health care professionals: uses and benefits. Pharm Ther. 2014;39(5):356–64.
39.
Kukula VA, Dodoo AA, Akpakli J, Narh-Bana SA, Clerk C, Adjei A, Awini E, Manye S, Nagai RA, Odonkor G, Nikoi C. Feasibility and cost of using mobile phones for capturing drug safety information in peri-urban settlement in Ghana: a prospective cohort study of patients with uncomplicated malaria. Malar J. 2015;14(1):411.CrossRefPubMedPubMedCentral
40.
41.
Xia F, Yang LT, Wang L, Vinel A. Internet of things. Int J Commun Syst. 2012;25(9):1101.CrossRef
42.
Ko J, Lu C, Srivastava MB, Stankovic JA, Terzis A, Welsh M. Wireless sensor networks for healthcare. Proc IEEE. 2010;98(11):1947–60.CrossRef
43.
Pratt N, Andersen M, Bergman U, Choi NK, Gerhard T, Huang C, Kimura M, Kimura T, Kubota K, Lai EC, Ooba N, Osby U, Park BJ, Sato T, Shin JY, Sundström A, Yang YH, Roughead EE. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013;22(9):915–24.PubMed
44.
Coloma PM, Trifirò G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013;36(3):183–97.CrossRefPubMed
45.
Patadia VK, Coloma P, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Fornari C, Pedersen L, van der Lei J, Sturkenboom M, Trifirò G. Using real-world healthcare data for pharmacovigilance signal detection—the experience of the EU-ADR project. Expert Rev Clin Pharmacol. 2015;8(1):95–102.CrossRefPubMed
46.
47.
Metadaten
Titel
From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources
verfasst von
Gianluca Trifirò
Janet Sultana
Andrew Bate
Publikationsdatum
01.02.2018
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 2/2018
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-017-0592-4

Weitere Artikel der Ausgabe 2/2018

Drug Safety 2/2018 Zur Ausgabe

Leading Article

Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country

short communication

Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study

Systematic Review

Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies

Original Research Article

All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

Original Research Article

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs

Original Research Article

Preferences of Patients and Pharmacists with Regard to the Management of Drug–Drug Interactions: A Choice-Based Conjoint Analysis